“Evaluation of Paclitaxel as a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC)”, ICRJ, vol. 1, no. 1, p. 2, Sep. 2025, doi: 10.70844/icrj.2025.1.2.